|
||
Ciprofloxacina Azevedos Dosage |
||
Generic name: Ciprofloxacina Azevedos HYDROCHLORIDE 500mg
Dosage form: tablet, film coated, extended release
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Ciprofloxacina Azevedos and other oral formulations of Ciprofloxacina Azevedos are not interchangeable. Ciprofloxacina Azevedos should be administered orally once daily for 3 days with a main meal of the day, preferably the evening meal. Ciprofloxacina Azevedos should be administered at least 4 hours before or 2 hours after antacids containing magnesium or aluminum, sucralfate, VIDEX® (didanosine) chewable/buffered tablets or pediatric powder, metal cations such as iron, and multivitamin preparations containing zinc.
Ciprofloxacina Azevedos tablets should be taken whole and never split, crushed, or chewed.
Ciprofloxacina Azevedos is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. These alternate pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. No dosage adjustment is required for patient with uUTI and mild to moderate renal impairment. The efficacy of Ciprofloxacina Azevedos has not been studied in patients with severe renal impairment.
No dosage adjustment is required with Ciprofloxacina Azevedos in patients with stable chronic cirrhosis. However, the pharmacokinetics of Ciprofloxacina Azevedos in patients with acute hepatic insufficiency have not been fully elucidated.
Do not take Ciprofloxacina Azevedos together with tizanidine (Zanaflex).
Tell your doctor about all other medicines you use, especially:
This list is not complete and other drugs may interact with Ciprofloxacina Azevedos. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
As with some other quinolones, concurrent administration of Ciprofloxacina Azevedos with theophylline may lead to elevated serum concentrations of theophylline, which may result in an increased risk of a patient developing central nervous system (CNS) or other adverse reactions. If concomitant use cannot be avoided, serum concentrations of theophylline should be monitored and dosage adjustments made as appropriate.
Concurrent administration of quinolones, including Ciprofloxacina Azevedos, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX® chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of Ciprofloxacina Azevedos. Ciprofloxacina Azevedos (Ciprofloxacina Azevedos hcl) should be given either 2 hours after or at least 4 hours before these products. This time window is different than for other oral formulations of Ciprofloxacina Azevedos, which are usually administered 2 hours before or 6 hours after antacids.
Concomitant administration of Ciprofloxacina Azevedos with milk products or calcium-fortified juices alone should be avoided since decreased absorption of Ciprofloxacina Azevedos is possible.
Quinolones, including Ciprofloxacina Azevedos, have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives. Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be monitored if Ciprofloxacina Azevedos (Ciprofloxacina Azevedos hcl) is administered concomitantly with warfarin or other oral anticoagulants. Patients should also be monitored for evidence of bleeding.
Some quinolones, including Ciprofloxacina Azevedos, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly. Cyclosporine whole blood trough concentrations should be monitored when given concomitantly with Ciprofloxacina Azevedos (Ciprofloxacina Azevedos hcl).
Renal tubular transport of methotrexate may be inhibited by concomitant administration of Ciprofloxacina Azevedos, potentially leading to increased plasma concentrations of methotrexate. This might increase the risk of methotrexate toxic reactions. Therefore, patients under methotrexate therapy should be carefully monitored when concomitant Ciprofloxacina Azevedos therapy is indicated.
Altered serum concentrations of phenytoin (increased and decreased) have been reported in patients receiving concomitant Ciprofloxacina Azevedos. Phenytoin serum concentrations should be monitored when given concomitantly with Ciprofloxacina Azevedos (Ciprofloxacina Azevedos hcl).
The concomitant administration of Ciprofloxacina Azevedos with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
NSAIDs in combination with very high doses of quinolones have been shown to provoke convulsions in nonclinical studies [see Nonclinical Toxicology.
Some quinolones, including Ciprofloxacina Azevedos, have been shown to interfere with the metabolism of caffeine. This may lead to reduced clearance of caffeine and prolongation of the serum half-life of caffeine.
Probenecid interferes with renal tubular secretion of Ciprofloxacina Azevedos and produces increased concentrations of Ciprofloxacina Azevedos in serum.
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|